Rebecca Johnson retweeted
Patient perspectives on the meaning of response after systemic therapy for #BladderCancer.
What does "response" mean to a patient? #BladderCancer advocates Rick Bangs @BladderCancerUS and @MargoWickersham join @shilpaonc @ClevelandClinic to discuss how bladder cancer patients ponse terminology at #IBCG2026, noting that patients often hear "complete response" as cancer gone for good, not a snapshot requiring ongoing discussion. #WatchNow > bit.ly/4hKmcfH #IBCG26 @IBCG_BladderCA @UroDocAsh
What does "response" mean to a patient? #BladderCancer advocates Rick Bangs @BladderCancerUS and @MargoWickersham join @shilpaonc @ClevelandClinic to discuss how bladder cancer patients ponse terminology at #IBCG2026, noting that patients often hear "complete response" as cancer gone for good, not a snapshot requiring ongoing discussion. #WatchNow > bit.ly/4hKmcfH #IBCG26 @IBCG_BladderCA @UroDocAsh
0
6
12
2,284
Rebecca Johnson retweeted
The MSKCC Genitourinary Oncology Service is looking for a motivated, patient-centered, clinical investigator with a focus on urothelial cancer. Join a great team focused on eradicating GU cancers!
msk.wd108.myworkdayjobs.com/MSKCC_Careers_…
msk.wd108.myworkdayjobs.com/MSKCC_Careers_…
2
17
60
6,395
Rebecca Johnson retweeted
More evidence showing skin toxicity with EVP is associated with disease response.
@HopkinsGBCI
. Here is one of the first papers showing this in 2023 from our group at Hopkins /GBCI: sciencedirect.com/science/articl…
@HopkinsGBCI
. Here is one of the first papers showing this in 2023 from our group at Hopkins /GBCI: sciencedirect.com/science/articl…
In advanced #UrothelialCarcinoma, treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer overall survival. ja.ma/4k88Qvf
0
5
17
1,339
Rebecca Johnson retweeted
REMINDER: Applications for BCAN’s 2026 Career Development Award close 10/26 at 5 p.m. ET.
The three-year, $250,000 grant supports early-career faculty establishing independent bladder cancer research programs.
The three-year, $250,000 grant supports early-career faculty establishing independent bladder cancer research programs.
1
4
6
912
Funding alert! 🚨 @BladderCancerUS has 2 research awards open for applications! Both $250k over 3 years.
Apply now to the Career Development (due 10/26) or Patient Centered Clinical (due 12/2) research award programs! 💸💸
bcan.org/bladder-cancer…
Apply now to the Career Development (due 10/26) or Patient Centered Clinical (due 12/2) research award programs! 💸💸
bcan.org/bladder-cancer…
0
1
2
119
Rebecca Johnson retweeted
Congrats to @angiesmith_uro and @FlorianSchroeck for receiving @theNCI funding for your R01, “Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy.” We appreciate your commitment to a patient-generated idea!
0
1
7
475
Rebecca Johnson retweeted
Applications are open for BCAN’s Patient-Centered Clinical Research Award: $250,000 over three years for faculty investigators launching research focused on the experiences and outcomes of people with bladder cancer.
2
7
10
837
Rebecca Johnson retweeted
Sexual health and intimacy deserve a place in the bladder cancer conversation from the very beginning of a patient’s journey. Our #BCANTT26 Think Tank session explored how we can make that happen. Thanks @UrologyTimes for the conversation! 🎥👇
WATCH: Armine K. Smith, MD, (@akfsurgeon) discusses key takeaways from a BCAN Think Tank session on sexual health and intimacy in modern bladder cancer care. #BCANTT26 @BladderCancerUS urologytimes.com/view/armine-k-…
1
5
11
1,000
Rebecca Johnson retweeted
What’s changing in bladder cancer treatment? Sandy Liu of @UCIrvineHealth and Amirali Salmasi, MD of @UCSD_Urology discussed treatments, clinical trials and bladder preservation at BCAN’s Fall Patient Summit.
1
1
1
560
Thrilled to see our work over years in #bladdercancer published in @Nature THANKS to patients/families consenting to our research autopsy program wanting to support others! Kudos to @HsiehLab @GavinHa #OmarMian #MingLam et al. @fredhutch @HutchPresident
nature.com/articles/s4158…
0
0
3
1,470
Don't miss your opportunity to apply for BCAN's 2026 Career Development Award! $250k over 3 years. Share widely! @JoshMeeks @UrogerliMD @ERPlimackMD @PGrivasMDPhD @MaxKates @SimaPorten @Parminder1699 @WilliamKimMD @DrRosenbergMSK
Applications are now open for BCAN’s 2026 Career Development Award! The three-year, $250,000 grant supports early-career faculty establishing independent bladder cancer research programs.
Apply by Oct. 26 at 5 p.m. ET
0
4
7
1,573
Rebecca Johnson retweeted
What happens when urologist oncologists, members of industry and patient advocates get together? #IBCG26 Creative ideas for how to improve the patient experience and create global standards for treatment and care of bladder cancer patients - and a lot of fun! cergroup #bladdercancer @IBCG_BladderCA @BladderCancerUS
@WorldBladderCan @BCAN_Research @urotoday @UroDocAsh
@WorldBladderCan @BCAN_Research @urotoday @UroDocAsh
2
3
6
418
Rebecca Johnson retweeted
Congratulations to this amazing group!
Honored that our @IBCG_BladderCA
consensus paper on "Optimal management of muscle-invasive bladder cancer" has received the @EUplatinum
Impact Award as the most influential work in its June 2026 issue!
Especially meaningful to see the 🌎 impact of this work, bringing together rtise to help guide evidence-based care, treatment sequencing, and the next generation of clinical trials for patients with MIBC worldwide.
Grateful to our co-authors, IBCG colleagues, and @UroDocAsh for his vision and commitment to improving bladder cancer outcomes.
Thank you @Albert0Briganti for this amazing recognition!
@CleClinicMD @CleClinicUro @caseccc
@EurUrolOncol @Uroweb @WorldBladderCan @FaltasLab @Uromigos @OncoAlert @BladderCancerUS @SpiessPhilippe @GTumors
Full paper here👇
doi.org/10.1016/j.euru…
1
4
14
1,479
Could not be more honored to have shared the stage with this amazing group of patient advocates. Thanks @UroDocAsh and @IBCG_BladderCA for giving us a voice. @MargoWickersham @michellecolero @WorldBladderCan @spsutkaMD @LAUrology_NL @BladderCancerUS
0
2
10
1,030
Rebecca Johnson retweeted
I haven’t posted much during #IBCG26, as wonderfully busy as it’s been, but I have to post this.
IMHO, the most important part of our meeting: the Patient Perspective panel.
A reminder of why we are all here. @IBCG_BladderCA @spsutkaMD @LAUrology_NL @BladderCancerUS @WorldBladderCan
IMHO, the most important part of our meeting: the Patient Perspective panel.
A reminder of why we are all here. @IBCG_BladderCA @spsutkaMD @LAUrology_NL @BladderCancerUS @WorldBladderCan
20 years ago, IBCG started with a small group around a table.
Later this month, friends and colleagues from around the world gather in Houston for #IBCG26. Two days around the table tackling some of the hardest questions in #BladderCancer, debating the evidence and challenging go next.
Looking forward to seeing you all!
@UrogerliMD @spsutkaMD @LAUrology_NL @shilpaonc @mouwlab @pjhensley11 @AndreaNecchi @AmirHorowitz @PGrivasMDPhD @karima_oualla @SimaPorten @joanfundi @marigfern
2
16
48
10,275
Rebecca Johnson retweeted
A powerful @IBCG_BladderCA #IBCG26 panel bringing together patient advocates from around the 🌎reminding us that the patient voice must remain at the center of everything we do in bladder cancer research and care.
@spsutkaMD @LAUrology_NL moderating a patient-centered discussion atter most and how we can do better for our patients.
@UroDocAsh @BladderCancerUS
@WorldBladderCan @MargoWickersham @BCAN_Research
@spsutkaMD @LAUrology_NL moderating a patient-centered discussion atter most and how we can do better for our patients.
@UroDocAsh @BladderCancerUS
@WorldBladderCan @MargoWickersham @BCAN_Research
0
9
33
2,172
Rebecca Johnson retweeted
Back from the BCAN Think Tank. Unique meeting because of the format.
🧩 Breakout rooms, not a podium: clinicians, scientists, pathologists, and advocates on the same case
🤝 People who would usually be in parallel sessions, in one room, brainstorming or disagreeing out loud
🗣️ A ry session, shaping the question
EV plus pembro, ctDNA in trials, AI in the clinic just a few of the great topics. Hope there will be even more next year!
Grateful to BCAN and the advocates who made every room sharper. What is on the agenda next year? 🧬
@BladderCancerUS #BladderCancer #GUonc #BCANTT26
🧩 Breakout rooms, not a podium: clinicians, scientists, pathologists, and advocates on the same case
🤝 People who would usually be in parallel sessions, in one room, brainstorming or disagreeing out loud
🗣️ A ry session, shaping the question
EV plus pembro, ctDNA in trials, AI in the clinic just a few of the great topics. Hope there will be even more next year!
Grateful to BCAN and the advocates who made every room sharper. What is on the agenda next year? 🧬
@BladderCancerUS #BladderCancer #GUonc #BCANTT26
2
6
15
860
Rebecca Johnson retweeted
Thank you to @CBSNews for highlighting our #research!
For many patients with muscle-invasive #BladderCancer, the standard of care is neoadjuvant systemic therapy followed by curative surgery to remove the bladder. For selected patients, bladder-preserving approaches are already an option, and the field is working to expand who can safely benefit.
Our #research at @WeillCornell @nyphospital combines patient-derived cancer organoids with AI to create “bio-digital avatars” of each patient's cancer.
This is team science, bringing together clinicians, laboratory scientists, computational biologists and mathematicians. We envision that these technologies could eventually help predict each patient’s response to treatment. Rigorous prospective validation will be essential before they can guide routine clinical care. @Cornell @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer @BladderCancerUS #FaltasLab
For many patients with muscle-invasive #BladderCancer, the standard of care is neoadjuvant systemic therapy followed by curative surgery to remove the bladder. For selected patients, bladder-preserving approaches are already an option, and the field is working to expand who can safely benefit.
Our #research at @WeillCornell @nyphospital combines patient-derived cancer organoids with AI to create “bio-digital avatars” of each patient's cancer.
This is team science, bringing together clinicians, laboratory scientists, computational biologists and mathematicians. We envision that these technologies could eventually help predict each patient’s response to treatment. Rigorous prospective validation will be essential before they can guide routine clinical care. @Cornell @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer @BladderCancerUS #FaltasLab
What if doctors could test cancer treatments on your tumor, without putting a single one of those treatments into your body? CBS News’ Riley Callanan reports.
10
24
74
21,454
Rebecca Johnson retweeted
So proud of @FaltasLab & his team with innovative research making national news! This is so promising & requires validation before use, Bishoy moves our field forward! @BladderCancerUS @HsiehLab @DrOmarMian @DrScottTagawa @cnsternberg @JoshMeeks @shilpaonc @montypal @neerajaiims
Thank you to @CBSNews for highlighting our #research!
For many patients with muscle-invasive #BladderCancer, the standard of care is neoadjuvant systemic therapy followed by curative surgery to remove the bladder. For selected patients, bladder-preserving approaches are already an option, and the field is working to expand who can safely benefit.
Our #research at @WeillCornell @nyphospital combines patient-derived cancer organoids with AI to create “bio-digital avatars” of each patient's cancer.
This is team science, bringing together clinicians, laboratory scientists, computational biologists and mathematicians. We envision that these technologies could eventually help predict each patient’s response to treatment. Rigorous prospective validation will be essential before they can guide routine clinical care. @Cornell @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer @BladderCancerUS #FaltasLab
1
5
22
2,261
Rebecca Johnson retweeted
Outstanding #BCANTT26 session on HER2!
#BladderCancer doesn't need to reinvent the HER2 wheel—cross-tumor learning from breast cancer is key.
📌 Key Highlights:
• Heterogeneity in HER2 requires effective ADC bystander effects (linkers matter!)
• Precision Biomarkers: guide the future of personalized HER2 therapy.
• Clinical Pearl: Don’t forget, NCCN guidelines now endorse T-DXd for HER2 IHC 2+ and up.
Kudos to the stellar lineup: @DrTFriedlander @IyerGopa Funda Meric-Bernstam Virginia Borges @BladderCancerUS
#BladderCancer doesn't need to reinvent the HER2 wheel—cross-tumor learning from breast cancer is key.
📌 Key Highlights:
• Heterogeneity in HER2 requires effective ADC bystander effects (linkers matter!)
• Precision Biomarkers: guide the future of personalized HER2 therapy.
• Clinical Pearl: Don’t forget, NCCN guidelines now endorse T-DXd for HER2 IHC 2+ and up.
Kudos to the stellar lineup: @DrTFriedlander @IyerGopa Funda Meric-Bernstam Virginia Borges @BladderCancerUS
0
9
18
3,264